From: P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia
 | CCyR rates, n/N (%) | |
---|---|---|
 | Dasatinib | Nilotinib |
Any mutation | 158/369 (43) | 18/77 (23) |
P-loop mutations | 61/141 (43) | NR |
   L248V | NR | 0/2 (0) |
   G250E | 19/51 (37) | 1/4 (25) |
   Y253F/H | 12/23 (52) | 0/8 (0) |
   E255K/V | 8/24 (33) | 0/6 (0) |
T315I | 0/20 (0) | 0/4 (0) |
F317L | 1/14 (7) | NR*†|
F359C/V | 14/27 (52) | 0/10 (0)* |